Literature DB >> 14987622

Increased vanilloid receptor VR1 innervation in vulvodynia.

Penelope Tympanidis1, Maria Anna Casula, Yiangos Yiangou, Giorgio Terenghi, Pauline Dowd, Praveen Anand.   

Abstract

Vulvodynia is characterised by painful burning sensation, allodynia and hyperalgesia in the region of the vulval vestibulus. While in many patients the cause of vulvodynia remains uncertain, we and others have previously shown increased intraepithelial and papillary innervation in vulvodynia. The vanilloid receptor VR1 (TRPV1) is expressed by nociceptors, and is triggered by capsaicin, noxious heat, protons, and chemicals produced during inflammation. In the present study we show increased papillary VR1 fibres by immunostaining and image analysis in vulvodynia tissues compared to controls (p<0.002). VR1 expression was found to be significantly increased when the percentage area immunostained was expressed as a ratio of VR1 to PGP 9.5, a pan-neuronal marker (P=0.01). VR1-positive fine epidermal fibres also appeared to be increased in vulvodynia tissues, by inspection. Fibres immunoreactive to the voltage-gated sodium channel SNS1/PN3 (Nav1.8), also expressed by nociceptors, were relatively scarce in both vulvodynia and control tissues. We hypothesize that increased expression of VR1 by nociceptors could mediate some of the symptoms in vulvodynia, for which systemic or topical specific VR1 antagonists may provide novel treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14987622     DOI: 10.1016/S1090-3801(03)00085-5

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  32 in total

Review 1.  Sensing the air around us: the voltage-gated-like ion channel family.

Authors:  Dennis Kim; James N Baraniuk
Journal:  Curr Allergy Asthma Rep       Date:  2007-05       Impact factor: 4.806

2.  Physiology and pharmacology of the vanilloid receptor.

Authors:  Angel Messeguer; Rosa Planells-Cases; Antonio Ferrer-Montiel
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

Review 3.  TRPV1: on the road to pain relief.

Authors:  Andrés Jara-Oseguera; Sidney A Simon; Tamara Rosenbaum
Journal:  Curr Mol Pharmacol       Date:  2008-11       Impact factor: 3.339

4.  A Local Inflammatory Renin-Angiotensin System Drives Sensory Axon Sprouting in Provoked Vestibulodynia.

Authors:  Zhaohui Liao; Anuradha Chakrabarty; Ying Mu; Aritra Bhattacherjee; Martha Goestch; Catherine M Leclair; Peter G Smith
Journal:  J Pain       Date:  2017-01-03       Impact factor: 5.820

Review 5.  Treatment of Vulvodynia: Pharmacological and Non-Pharmacological Approaches.

Authors:  Natalie O Rosen; Samantha J Dawson; Melissa Brooks; Susan Kellogg-Spadt
Journal:  Drugs       Date:  2019-04       Impact factor: 9.546

Review 6.  Small molecule vanilloid TRPV1 receptor antagonists approaching drug status: can they live up to the expectations?

Authors:  Arpad Szallasi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-06-14       Impact factor: 3.000

7.  Capsaicin and the treatment of vulvar vestibulitis syndrome: a valuable alternative?

Authors:  Filippo Murina; Gianluigi Radici; Vanda Bianco
Journal:  MedGenMed       Date:  2004-12-08

8.  Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial.

Authors:  David C Foster; Merrill Beth Kotok; Li-Shan Huang; Arthur Watts; David Oakes; Fred M Howard; Ellen L Poleshuck; Chris J Stodgell; Robert H Dworkin
Journal:  Obstet Gynecol       Date:  2010-09       Impact factor: 7.661

9.  The emerging role of TRP channels in mechanisms of temperature and pain sensation.

Authors:  Gina M Story
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

10.  Chemical synthesis, pharmacological characterization, and possible formation in unicellular fungi of 3-hydroxy-anandamide.

Authors:  L De Petrocellis; R Deva; F Mainieri; M Schaefer; T Bisogno; R Ciccoli; A Ligresti; K Hill; S Nigam; G Appendino; V Di Marzo
Journal:  J Lipid Res       Date:  2008-11-17       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.